Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data

PURPOSE: Second-line treatment with ramucirumab-paclitaxel has demonstrated statistically significant and clinically meaningful survival outcomes compared to paclitaxel-alone in patients with advanced gastric cancer (HR=0.807, 95% CI 0.678–0.962; P=0.017). Post hoc, exploratory analyses of RAINBOW p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Muro, Kei, Jen, Min-Hua, Cheng, Rebecca
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6433106/
https://ncbi.nlm.nih.gov/pubmed/30962715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S193739
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky